Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing

BACKGROUND: Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC). A better explanation for the variability in the pharmacokinetics (PK) of mitotane, and the optimization and individualization of mitotane treatment, is desirable for patients. OBJECTIVES: This study...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Pharmacokinet
Autori principali: Yin, Anyue, Ettaieb, Madeleine H. T., Swen, Jesse J., van Deun, Liselotte, Kerkhofs, Thomas M. A., van der Straaten, Robert J. H. M., Corssmit, Eleonora P. M., Gelderblom, Hans, Kerstens, Michiel N., Feelders, Richard A., Eekhoff, Marelise, Timmers, Henri J. L. M., D’Avolio, Antonio, Cusato, Jessica, Guchelaar, Henk-Jan, Haak, Harm R., Moes, Dirk Jan A. R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2020
Soggetti:
Original Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7809008/
https://ncbi.nlm.nih.gov/pubmed/32607875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-020-00913-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi